Related Experiment Video
Updated: Jun 8, 2025

05:55
Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System
Published on: December 21, 2019
6.7K
DNA Sensor ABCF1 Phase Separates With cccDNA to Inhibit Hepatitis B Virus Replication.
Caiyue Ren1, Zhaoying Zhang1, Yutong Dou1
1Key Laboratory for Experimental Teratology of Ministry of Education and Department of Immunology, School of Basic Medical Sciences, Cheeloo Medical College, Shandong University, Jinan, Shandong, 250012, China.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
|November 5, 2024
Summary
ATP-binding cassette subfamily F member 1 (ABCF1) restricts Hepatitis B virus (HBV) replication by forming phase-separated condensates with HBV cccDNA. This dual action activates innate immunity and inhibits viral transcription.
Area of Science:
- Virology
- Immunology
- Molecular Biology
Background:
- Hepatitis B virus (HBV) covalently closed circular DNA (cccDNA) is crucial for viral persistence.
- The host innate immune response to cccDNA remains incompletely understood.
Purpose of the Study:
- To identify host factors that interact with cccDNA and restrict HBV replication.
- To elucidate the mechanism by which the host innate immune system combats cccDNA.
Main Methods:
- cccDNA-hepatic protein interaction profiling.
- Identification and characterization of ATP-binding cassette subfamily F member 1 (ABCF1) as a cccDNA-binding protein.
- Analysis of phase separation, interferon pathway activation, and HBV transcription inhibition.
Main Results:
- ABCF1 was identified as a novel cccDNA-binding protein and a host restriction factor for HBV.
- ABCF1 recognizes cccDNA and forms phase-separated condensates, activating type I/III interferon (IFN-I/III) signaling.
- ABCF1 inhibits HBV transcription by preventing Pol II accumulation on cccDNA.
- HBV counteracts this by reducing ABCF1 expression via HBx-mediated degradation of SOX4.
Conclusions:
- ABCF1-cccDNA phase separation provides a dual mechanism for host defense against HBV by activating innate immunity and inhibiting viral transcription.
- This study reveals a novel host-pathogen interaction and offers a potential therapeutic target for HBV infection.

